This review summarizes the binding potency and vascular activity of peptide and nonpeptide endothelin receptor antagonists.
Offers a reference for endothelin antagonist potency; leaves open optimal clinical use pending randomized trials.
The endothelins are a family of potent vasoconstrictors, some of which also have vasodilatory activity. In many diseases associated with tissue hypoxia or ischemia and in diseases in which vasoconstriction plays a role, the circulating levels of endothelin are higher than in healthy, control subjects. These findings stimulated research aimed at discovering endothelin receptor antagonists. This review focuses on the binding potency and vascular activity of these new peptide and nonpeptide endothelin receptor antagonists.
No takes yet. Share an insight, caveat, or question.
Suzanne Moreland (1994) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: